Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (%EF%BF%BD%EF%BF%BDkrbec Vesna) .

1 - 10 / 192
Na začetekNa prejšnjo stran12345678910Na naslednjo stranNa konec
1.
Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation
Mirta Koželj, Samo Zver, Vesna Zadnik, 2013, izvirni znanstveni članek

Povzetek: Background. Tandem autologous hematopoietic stem cell transplantation (ta-HSCT) is a standard treatment for multiple myeloma (MM). Patients receive a high-dose cyclophosphamide (CY), followed by two myeloablative cycles of melphalan (MEL). There are scarce data about long term cardiotoxicity. Patients and methods. We studied 12 patients (62.25 8.55 years) six years after the completion of MM treatment with ta-HCST. Late cardiotoxic effects were evaluated clinically and echocardiographically. Results. None of the patients developed clinical signs of heart failure, all were in sinus rhythm and NT-pro BNP concentration was elevated (778 902.76 pg/mL). The left ventricular (LV) size remained normal. The LV ejection fraction did not decrease (73.75 5.67%, 69.27 6.13%, p = NS). The LV diastolic function parameters (E, A, ratio E/A and A/a) did not change significantly. In tissue Doppler parameters we observed a nonsignificant decrease in Em (10.26 2.63 cm/s, 7.57 1.43 cm/s) and Sm velocities (8.7 0.87 cm/s, 7.14 1.17 cm/s, p = NS). The E/Em values were in an abnormal range (8.66 1.05, 10.55 2.03). Conclusions. The treatment of MM with ta-HSCT, during which patients receive a high dose CY followed by two myeloablative cycles of MEL, causes mild, chronic, partially reversible and clinically silent cardiotoxic side-effects. However, ta-HSCT in patients with MM is a safe regarding cardiotoxic side effects, but, because of increasing life expectancy needs long term attention.
Ključne besede: cardiotoxicity, echocardiography, myeloma
Objavljeno v DiRROS: 22.03.2024; Ogledov: 42; Prenosov: 15
.pdf Celotno besedilo (288,46 KB)

2.
Assessment of the tumourigenic and metastatic properties of SK-MEL28 melanoma cells surviving electrochemotherapy with bleomycin
Vesna Todorović, Gregor Serša, Vid Mlakar, Damjan Glavač, Maja Čemažar, 2012, izvirni znanstveni članek

Povzetek: Background. Electrochemotherapy is a local treatment combining chemotherapy and electroporation and is highly effective treatment approach for subcutaneous tumours of various histologies. Contrary to surgery and radiation, the effect of electrochemotherapy on metastatic potential of tumour cells has not been extensively studied. The aim of the study was to evaluate the effect of electrochemotherapy with bleomycin on the metastatic potential of human melanoma cells in vitro. Materials and methods. Viable cells 48 hours after electrochemotherapy were tested for their ability to migrate and invade through Matrigel coated porous membrane. In addition, microarray analysis and quantitative Real-Time PCR were used to detect changes in gene expression after electrochemotherapy. Results. Cell migration and invasion were not changed in melanoma cells surviving electrochemotherapy.Interestingly, only a low number of tumourigenesis related genes was differentially expressed after electrochemotherapy. Conclusions. Our data suggest that metastatic potential of human melanoma cells is not affected by electrochemotherapy with bleomycin, confirming safe role of electrochemotherapy in the clinics.
Objavljeno v DiRROS: 21.03.2024; Ogledov: 60; Prenosov: 36
.pdf Celotno besedilo (640,99 KB)
Gradivo ima več datotek! Več...

3.
Inguinal or inguino-iliac/obturator lymph node dissection after positive inguinal sentinel lymph node in patients with cutaneous melanoma
Nebojša Glumac, Marko Hočevar, Vesna Zadnik, Marko Snoj, 2012, izvirni znanstveni članek

Povzetek: The aim of the study was to determine whether the presence of inguinal sentinel lymph node (SLN) metastases smaller than 2 mm (micrometastases) subdivided according to the number of micrometastases predicts additional, non-sentinel inguinal, iliac or obturator lymph node involvement in completion lymph node dissection (CLND). Positive inguinal SLN was detected in 58 patients (32 female, 26 male, median age 55 years) from 743 consecutive and prospectively enrolled patients with primary cutaneous melanoma stage I and II who were treated with SLN biopsy between 2001 and 2007. Micrometastases in inguinal SLN were detected in 32 patients, 14 were single, 2 were double, and 16 were multiple. Twenty-six patients had macrometastases. No patient with any micrometastases or a single SLN macrometastasis in the inguinal region had any iliac/obturator non-sentinel metastases after CLND in our series. Furthermore, no patient with single SLN micrometastasis in the inguinal region had any non-sentinel metastases at all after CLND in our series. In these cases respective CLND might be omitted.
Objavljeno v DiRROS: 21.03.2024; Ogledov: 48; Prenosov: 19
.pdf Celotno besedilo (307,79 KB)

4.
The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice
Brigita Gregorič, Vesna Zadnik, Barbara Jezeršek Novaković, 2012, izvirni znanstveni članek

Povzetek: Background. Due to superior results observed with the addition of rituximab into treatment of patients with the diffuse large B-cell lymphoma (DLBCL),the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen and its variants became the standard initial treatment of these patients. However, the treatment recommendations are based on resultsof clinical studies while the conditions of routine treatment are far different from the ones in clinical studies. The aim of this retrospective study was therefore to compare the treatment results of routinelz treated patients with the DLBCL to results reported by some larger studies. Patients and methods. Two hundred and ninety five patients with the DLBCL were treated between 2004 and 2008 according to the then protocol with R-CHOP or R-CHOP-like regimens at the Institute of Oncology Ljubljana. Treatment response was evaluated according to Chesonʼs criteria and the disease-free andoverall survival by means of Kaplan Meier survival curves. Results. Response to treatment in our evaluation diverged from the reported one predominately in the low risk group (international prognostic index [IPI] categorisation) and in the very good prognosis group (revised international prognostic index (R-IPI) categorisation). The determined complete response (CR) rates in other IPI and R-IPI groups were generally within expectations. Also in the disease-free survival the largest discrepancy occurred in the low-risk patient group (3 year disease-free survival rate of 75%) and in the very good prognosis group (4 year disease-free survival rate of 59%). In all other IPI risk groups, the disease-free survival at 3 zears (low intermediate risk 76%, high intermediate risk group 57%, and high risk group 53%) agreed verz well with the quoted ones. Slightly worse was the compliance of the 4 year disease-free survival rates (72% in the good prognosis and 51% in the poor prognosis group) with the results from the literature. The 3 year overall survival rates (low risk patients 87%, high intermediate risk 61% and high risk patients 51%) were somewhat worse than the reported ones in all IPI subgroups except in the low intermediate risk group (82%). On the other hand, the 4 year overall survival rates of the R-IPI categories (94% in the very good prognosis group, 80% in the good prognosis group, 56% in the poor prognosis group) were much better correlated with the data from the literature. Conclusions. In total, the treatment outcomes of routinely treatedpatient with the DLBCL at our institute are quite encouraging when compared to results of some larger studies. There are probably no dilemmas about how to treat young good prognosis patients and patients aged over 60 years at present. However, the 5 year overall survival rate of 76% for the young poor prognosis group is unsatisfying and needs to be improved. At present, quite a few studies are underway to clarify which of the regimens will perform best in this population.
Ključne besede: diffuse large B-cell lymphoma, R-CHOP, treatment result, routine treatments
Objavljeno v DiRROS: 21.03.2024; Ogledov: 58; Prenosov: 24
.pdf Celotno besedilo (621,34 KB)

5.
Morphological and molecular characterization of Micromeria croatica (Lamiaceae), an endemic and potentially valuable horticultural species of the Dinaric Alps
Zlatko Liber, Ivan Radosavljević, Zlatko Šatović, Marija Hodja, Vesna Židovec, Faruk Bogunić, Dalibor Ballian, Danijela Stešević, Sven D. Jelaska, Dario Kremer, 2023, izvirni znanstveni članek

Povzetek: Due to climate extremes and limited natural resources, especially water, we can expect increased demand in the future for species that can better tolerate climate extremes such as drought. One potentially valuable horticultural species is the endemic species of the Dinaride Mountains Micromeria croatica (Pers.) Schott (family Lamiaceae). It grows in the crevices of carbonate rocks, extending from an altitude of 150 m to more than 2000 m. This study aims to provide additional insight into the genetic and morphological diversity of this endemic species, focusing on valuable horticultural traits. To achieve this goal, morphological and molecular analyses were performed on ten natural populations. Through STRUCTURE and PCoA analyses, ten M. croatica populations were placed into western and eastern genetic groups, with several individuals from western populations assigned to the eastern group and vice versa. These atypical individuals assigned to the new genetic group by BAPS analysis indicate gene flow between western and eastern populations. Similarly, an analysis of molecular variance revealed fewer genetic differences than within studied populations. Both PCA and CANDISC analysis based on eleven morphological traits largely confirmed the existence of two slightly different genetic groups. Two populations containing plants with the most flowers per shoot, one with white-flowered individuals, one with the roundest leaves, and one with the narrowest leaves proved to be the most horticulturally valuable. The genetic and morphological variability found should be a sufficient basis for the potential selection of M. croatica populations and individuals for horticultural purposes.
Ključne besede: morphological characterization, molecular characterization, Micromeria croatica (Lamiaceae), Dinaric Alps
Objavljeno v DiRROS: 19.03.2024; Ogledov: 54; Prenosov: 31
.pdf Celotno besedilo (3,55 MB)
Gradivo ima več datotek! Več...

6.
Lymphedema following cancer therapy in Slovenia : a frequently overlooked condition?
Tanja Planinšek Ručigaj, Nada Kecelj, Vesna Tlaker Žunter, 2010, izvirni znanstveni članek

Povzetek: Introduction. Secondary lymphedema following cancer therapy is a frequent, often painful, quality of life disturbing condition, reducing the patients' mobility and predisposing them to complications, e.g. infections and malignancies. The critical aspect of lymphedema therapy is to start as soon aspossible to prevent the irreversible tissue damage. Patients and methods. Weperformed a retrospective study of patients with lymphedema, treated at the Department of Dermatovenereology, University Medical Center Ljubljana, from January 2002 to June 2010. The patientsć demographic and medical data were collected, including type of cancer, type and stage of lymphedema, and time tofirst therapy of lymphedema. The number of referred patients with lymphedema following the therapy of melanoma, breast cancer, and uterine/cervical cancer, was compared to the number of patients expected to experience lymphedema following cancer therapy, calculated from the incidence reported in the literature. Results. In the period of 8.5 years, 543 patients (432 females, 112 males) with lymphedema were treated. The results show that probably many Slovenian patients with secondary lymphedema following cancer therapy remain unrecognized and untreated or undertreated. In the majority of our patients, the management of lymphedema was delayedč on average, the patients first received therapy for lymphedema 3.6 years after the first signsof lymphedema. Conclusions. To avoid a delay in diagnosis and therapy, and the complications of lymphedema following cancer therapy, the physician should actively look for signs or symptoms of lymphedema during the follow-up period, and promptly manage or refer the patients developing problems.
Ključne besede: rak (medicina), zdravljenje, limfedem
Objavljeno v DiRROS: 18.03.2024; Ogledov: 50; Prenosov: 21
.pdf Celotno besedilo (416,52 KB)

7.
8.
9.
General position polynomials
Vesna Iršič, Sandi Klavžar, Gregor Rus, James Tuite, 2024, izvirni znanstveni članek

Povzetek: A subset of vertices of a graph $G$ is a general position set if no triple of vertices from the set lie on a common shortest path in $G$. In this paper we introduce the general position polynomial as $\sum_{i \geq 0} a_i x^i$, where $a_i$ is the number of distinct general position sets of $G$ with cardinality $i$. The polynomial is considered for several well-known classes of graphs and graph operations. It is shown that the polynomial is not unimodal in general, not even on trees. On the other hand, several classes of graphs, including Kneser graphs $K(n,2)$, with unimodal general position polynomials are presented.
Ključne besede: general position set, general position number, general position polynomial, unimodality, trees, Cartesian product of graphs, Kneser graphs
Objavljeno v DiRROS: 28.02.2024; Ogledov: 77; Prenosov: 65
.pdf Celotno besedilo (384,07 KB)
Gradivo ima več datotek! Več...

10.
Incidenca raka v prvem letu epidemije covida-19
Vesna Zadnik, Tina Žagar, Nika Bric, Mojca Birk, Amela Duratović Konjević, Ana Mihor, Katarina Lokar, Sonja Tomšič, 2023, strokovni članek

Povzetek: Uvod: Število novih diagnoz raka (incidenca) se v Sloveniji v zadnjem desetletju povečuje za povprečno 1,6 % na leto. V letu 2020, prvem letu omejitvenih ukrepov zaradi epidemije covida19, smo s platformo OnKOvid predvideli 3–8-odstotni padec novih diagnoz raka. Namen je predstaviti uradno incidenco raka za Slovenijo za leto 2020 in ugotoviti, kolikšen je bil dejansko manko novih diagnoz raka. Metode: V Registru raka Republike Slovenije smo v skladu z mednarodnimi pravili registrirali vse nove primere raka pri prebivalcih s stalnim prebivališčem v Sloveniji. Primerjali smo jih z registrirano incidenco za 2019, modelno incidenco za 2020, preliminarnimi rezultati OnKovida in dostopnimi rezultati incidence iz registrov raka iz drugih držav. Rezultati: V letu 2020 je za rakom zbolelo 15.096 oseb v Sloveniji (7.034 žensk, 8.002 moška). Glede na modelno oceno incidence za leto 2020 gre za manko 1.854 oseb (10,9 %; 11,6 % žensk, 10,4 % moških). Pri tem je za 10,5 % manj ugotovljenih rakov v omejenem stadiju, najbolj izrazito v starosti 50–69 let (za 13,2 %). Upad je primerljiv s poročili iz Anglije, ZDA in Kanade ter deloma večji kot na Škotskem in Švedskem. Najbolj izrazit upad novih diagnoz raka ugotavljamo pri nemelanomskem kožnem raku (23 %, najbolj po 50. letu), raku prostate (15,9 %, najbolj v omejenem stadiju), pljučnem raku (8,9 %, 60–64 let, v razširjenem stadiju), raku dojk (8,3 %, 45–64 let), ne-Hodgkinovem limfomu (9 %) in levkemijah (11,6 %). Pri kožnem melanomu, raku debelega črevesa in danke ni bilo primanjkljaja. Zaključek: Upad incidence raka v letu 2020 gre verjetno na račun omejitvenih ukrepov, reorganizacije zdravstva in z zdravjem povezanega vedenja med epidemijo covida-19, beležijo jo v več državah. Med epidemijami je potrebno nemoteno izvajanje onkologije.
Ključne besede: rak, incidenca, register raka, epidemija, covid-19
Objavljeno v DiRROS: 26.02.2024; Ogledov: 121; Prenosov: 23
.pdf Celotno besedilo (301,68 KB)

Iskanje izvedeno v 0.42 sek.
Na vrh